quadriplegia, his physical examination was significant for 0/5 strength in both upper and lower extremities, complete sensory loss below the C-5 dermatome, and absence of all reflexes. He began receiving dexamethasone and underwent preparation for emergency spinal decompression and possible lesion biopsy.
Surgery. Laminectomies of the C-4 to T-1 vertebrae were performed with preservation of the facet joints. The dura was opened in the midline and tented laterally, revealing a grossly expanded cord, particularly marked at the C5-6 levels. Using microsurgical techniques the arachnoid was opened and a midline myelotomy was made extending just rostral and caudal to the expanded cord. The underlying tissue was diffusely hemorrhagic and discolored. The hematoma was allowed to express itself and tissue was sent for pathological analysis. Resection of grossly abnormal tissue was performed while taking care not to disrupt what appeared to be a ventral plane between the hemorrhagic tissue and more normalappearing cord. The patient was successfully extubated and transferred to the neurological intensive care unit.
Pathology. The pathology specimens consisted of sheets and vague groups of the tumor cells in a hemorrhagic background ( Fig. 2A) . The tumor cells were mainly grouped around vessels without a distinct histoarchitecture (Fig. 2B) . Individual cells had a primitive appearance with large, pleomorphic nuclei and scant cytoplasm. Nuclear molding was prominent in several areas. Abundant karyorrhectic debris was present together with the tumor cell aggregates (Fig. 2B ). Immunohistochemical stains revealed that a small subset of tumor cells stained positively for glial fibrillary acidic protein and synaptophysin (not shown), suggesting some degree of glial and neuronal differentiation. The tumor cells did not express CD99, a relatively specific marker for Ewing sarcoma/ PNET (Fig. 2C ). The MIB-1 (Ki 67) proliferation index was approximately 30% to 40% (Fig. 2D ). Fluorescence in situ hybridization analysis using the EWSR1 break apart probe did not reveal a chromosome 22q12 rearrangement. These findings are most consistent with a diagnosis of a CNS PNET.
Postoperative Course. Within hours of being transferred from the operating room to the neurological intensive care unit the patient required reintubation due to respiratory difficulty believed to be secondary to postsurgical cord edema. Further imaging workup did not reveal metastases or other possible primary lesions. A tracheostomy was performed and the patient was subsequently discharged to a skilled nursing facility with quadriplegia (American Spinal Injury Association Grade A) and was ventilator-dependent but otherwise stable. He was treated with 6 cycles of vincristine, cyclophosphamide, carboplatin, and etoposide (COPE). At a follow-up visit 28 months after surgery, the patient remained progression free and stable.
Case 2
Presentation. This 35-year-old man with no significant medical history was first examined in an office consultation for progressive back and leg pain of 6 months duration. The leg pain was radicular in nature and particularly notable around the knees. His back pain was reported to awaken him at night. On physical examination his motor function, sensory function, gait, and reflexes were intact. Magnetic resonance imaging was obtained, which showed a 1.4 × 4.7 cm intradural mass that extended from the level of the T12-L1 intervertebral space to the L1-2 intervertebral space, with the rostral aspect of the mass abutting the conus medullaris. The mass appeared isointense on T1-weighted sequences and moderately hyperintense on T2-weighted sequences (Fig. 3) . Contrastenhanced images were not available. Myxopapillary ependymoma and nerve sheath tumor were considered in the differential diagnosis. Elective surgical intervention was recommended with the goal of GTR.
Surgery. Bilateral laminectomies from T-12 to L-2 with preservation of the facet joints were performed. The dura was opened in the midline and tented laterally, exposing the nerve roots of the cauda equina. Using microsurgical techniques, the arachnoid was incised and a dissection plane was identified between the roots of the cauda equina and the tumor. The highly vascular and friable tumor was well circumscribed without a true capsule, but there was intricate association with, and attachment to, the rootlets of the cauda equina. The tumor was internally debulked and the margins carefully delivered into the surgical field. Intricate tumor attachments to the surrounding rootlets were removed piecemeal. A radical resection (but not GTR) was achieved as there remained small tumor remnants inferiorly that could not be safely resected. The patient was extubated and transferred to the recovery unit uneventfully.
Pathology. On microscopic examination the specimen was highly cellular and predominantly arranged in patternless sheets of cells ( Fig. 4A and B) . Primitive-appearing, medium-sized cells with indistinct cell borders were present. The nuclei of the neoplastic cells were round-to-oval with stippled or compact chromatin and occasional nucleoli. Nuclear molding was evident. Occasional ill-defined rosettelike structures were noted (not shown), resembling Homer-Wright rosettes. Many mitotic figures and karyorrhectic bodies were noted (Fig. 4B ). Vast areas of tumor necrosis were observed (not shown). In immunohistochemical preparations the neoplastic cells diffusely and strongly expressed CD99 (Fig. 4C) . The neoplastic cells did not express synaptophysin or glial fibrillary acidic protein (not shown). The MIB-1 (Ki 67) proliferation index was 20%-30% (Fig. 4D) . Fluorescence in situ hybridization analysis revealed a chromosome 22q12 rearrangement. These findings are consistent with a diagnosis of Ewing sarcoma/ PNET.
Postoperative Course. The patient awoke from surgery neurologically intact. His preoperative back pain resolved but his leg pain remained, and he subsequently began receiving gabapentin. Postoperative MR imaging of the spine demonstrated a 9-mm residual nodule at the inferior portion of the resection. Further imaging workup did not reveal metastases or other possible primary lesions. A protocol of focal external beam radiation therapy and chemotherapy was recommended, but the patient returned to his home country and was lost to follow-up approximately 2 months following surgery.
Discussion

History and Classification
Primary spinal PNETs are histologically indistinguishable from other neural axis PNETs. The earliest recognized case report of a spinal PNET is from a paper by Smith et al. published in 1969. 87 Their use of the term PNET is problematic, however, because the nomenclature and criteria for diagnosing PNET were not formally introduced until 1973 by Hart and Earle, 35 and therefore it is unclear whether or not the tumor they reported actually met the criteria for a PNET. The original classification scheme for PNETs arose from the hypothesis that all tumors of this category share a common progenitor cell. However, in 1993 the WHO determined that this claim could not be substantiated. 53, 83 The WHO description of PNETs has evolved such that several tumors once included under this nomenclature are now understood as distinct diagnoses, including such notable examples as medulloblastoma, atypical teratoid/rhabdoid tumors, and pineoblastomas. 54, 55, 64 In addition, tumors that exhibit more extensive differentiation are considered to be distinct diagnoses, including neuroblastomas, ganglioneuroblastomas, medulloepitheliomas, and ependymoblastomas. 55, 64 Similarly, it has been argued that embryonal tumor with abundant neuropil and true rosettes represents a distinct entity as well. 21, 30, 64 Those tumors currently understood as PNETs are further divided into 2 categories: CNS PNETs and Ewing sarcoma/PNETs. They can both be found anywhere along the neural axis. Genetic and immunohistopathological analyses are used to distinguish these 2 subtypes, but the clinical significance of this segregation continues to remain unclear.
Epidemiology
Little reliable information is available on the incidence of primary spinal PNETs. 64, 85 A recent large series of patients indicates that PNETs represent less than 1% of primary spinal tumors. 22 However, whereas primary spinal PNETs are rare, they are perhaps more common than has been previously recognized. Our review of the literature yielded 82 cases (including ours) reported since 1969 (Table 1) . Interestingly, the majority of these cases were reported within the last decade, possibly indicating an increased awareness of the diagnosis (Fig. 5 ). The assertion that primary spinal PNETs are most prevalent in the pediatric and young-adult populations and are observed more commonly in males than in females is supported by our analysis of reported cases. 40, 45, 48 The median age at the time of diagnosis was 24 years (range 0.25-70 years) and there was a nearly 2:1 male sex preponderance (Table 1) .
Genetics
Much of the revision of the classification schema for PNETs has resulted from advances in their genetic characterization. It is important to note that there is currently no known genetic distinction between cranial/supratentorial PNETs and spinal PNETs; thus genetic analyses from intracranial PNETs may also inform our understanding of spinal PNETs. 64 This idea is supported by the fact that both CNS PNETs and Ewing sarcoma/PNETs can each be found either intracranially or intraspinally. Thus, anatomical location cannot be used to distinguish PNETs.
Cytogenetic analysis of CNS PNETs has revealed several notable alterations. These include RASSF1A promoter methylation, expression of the Neuro D family of basic helix-loop-helix transcription factors (bHLH), and expression of achaete scute, a transcription factor with homology to Neuro D. 64 Using fluorescence in situ hybridization analysis of 30 patients with PNETs, Behdad and Perry 7 identified several MYC gene amplifications, including MYCN and MYCC, and found that polysomies of chromosomes 2 and 8 are significant prognostic indicators of poor survival in adult patients with PNET. In addition, the NOTCH1 gene, neuroglial differentiation gene SOX2, and the bHLH suppressor gene ID1 have been shown to be upregulated in supratentorial PNETs. 80 Several studies have demonstrated that chromosomal deletions at 16p and 19p are common in CNS PNETs. 12, 41 Interestingly, CNS PNETs generally lack the i(17)q abnormality present in 30%-50% of medulloblastoma specimens, a feature greatly responsible for their reclassification into distinct entities. 29, 55, 64 Ewing sarcoma/PNETs demonstrate the characteristic translocation (11;22) (q24;q12) in more than 90% of cases. 6, 15, 67 Most commonly, this involves a rearrangement of the EWS and FL1 genes (85%) or EWS and ERG genes (10%). 6, 16, 88, 98 The presence of an (11;22) (q24;q12) translocation is therefore the strongest diagnostic tool in identifying Ewing sarcoma/PNET. The presence of this translocation may be confirmed by either fluorescence in situ hybridization or reverse transcription polymerase chain reaction. Upregulation of the MIC2 gene, which encodes the surface protein CD99, is also usually present in Ewing sarcoma/PNETs and is another useful diagnostic indicator. The membrane proteins HNK1 and CAV1 have been implicated in Ewing sarcoma/PNET as well. 62 
Histopathology and Immunohistochemistry
Central nervous system PNETs are generally characterized by poorly differentiated, often densely packed cells with high nuclear-to-cytoplasmic ratios. 64 Both nuclear pleomorphism and molding are often observed, as demonstrated in Case 1. Individual cells may exhibit differentiation along neuronal, astrocytic, or ependymal lineages with corresponding nuclear and cytoplasmic features. Tumor cells can be arranged in a number of patterns, including parallel streams, palisades, and/or single file. HomerWright rosettes are often present, but not definitive. Degenerate regions usually show calcification and many tumors demonstrate vascular-endothelial proliferation.
Electron microscopy of CNS PNETs often reveals scant cytoplasmic organelles and reflects individual lineage differentiation. Compact arrays of cytoplasmic glial filaments suggest glial differentiation, while the presence of growth cones would support ganglionic differentiation.
The immunohistochemical profile of CNS PNETs is These cells may also express S100, neuron-specific enolase, and Leu-7 (CD-57). 82 Glial fibrillary acidic protein is expressed in tumors with astrocytic differentiation. Mitotic activity is highly variable. In general, intertumor variability is too high to base diagnosis on a single antigen expression pattern. 64 Ewing sarcoma/PNETs are histologically characterized by sheets of primitive-appearing cells with thin rims of periodic acid-Schiff positive, diastase-sensitive, glycogen-rich cytoplasm. 25 Some degree of cytoplasmic clearing may also be evident. Homer-Wright rosettes are sometimes present. Most tumors stain at least focally with neuronal markers such as synaptophysin and neuron-specific enolase. Cytokeratin stains are usually negative. 64 The membrane proteins FLI1, HNK1, and CAV1 are commonly expressed in Ewing sarcoma/PNETs. 18, 26, 27, 63, [69] [70] [71] 91 In addition, upregulation of the MIC2 gene in Ewing sarcoma/PNET results in a high degree of expression of the transmembrane glycoprotein CD99. Conversely, CD99 is generally not expressed in CNS PNETs. 4, 95 In a study of 402 confirmed cases of Ewing sarcoma/PNET, Llombart-Bosch et al. 62 found that 99% expressed CD99 either focally or globally. However, MIC2/CD99 is also highly expressed in a number of other tumors including ependy- 
Clinical Presentation
As demonstrated by our 2 case illustrations, the clinical presentation of spinal PNETs is variable. The development of pain, paresthesias, weakness, or incontinence over several weeks to months is nonspecific but commonly observed (Table 1) . Conversely, intratumoral hemorrhage resulting in acute neurological decline, such as that observed in our first case, has not been previously reported. Our second case represents a more typical subacute presentation.
Radiographic Findings
The radiographic findings of spinal PNETs vary from patient to patient and are generally not helpful in differentiating them from other primary spinal lesions such as ependymoma or astrocytoma. Magnetic resonance imaging with and without Gd contrast is the imaging modality of choice in detecting spinal PNETs. As demonstrated by our reported cases, spinal PNETs are typically hypo-to isointense on T1-weighted MR imaging and iso-to hyperintense on T2-weighted imaging. There is often minimal contrast enhancement and, less frequently, the appearance of cystic regions. Fluorine-18-labeled fluorodeoxyglucose PET-CT is another useful adjunct in guiding the management of patients with these tumors; in particular, it can be helpful in detecting metastatic disease and tumor progression. 20, 68, 94 Determining that the tumor is restricted to the spine is important because spinal PNETs can be metastatic from extraspinal primary lesions at presentation. Conversely, primary spinal PNETs may metastasize extraspinally (Table 2) .
Diagnosis
A definitive diagnosis of PNET can only be made after tumor tissue is obtained from a limited biopsy or a radical resection specimen. The specific diagnostic criteria used are as described in the clinical cases and in the section on histopathology. In terms of subtyping, in our first case the diagnosis of CNS PNET was based on characteristic histology, supportive immunohistochemistry revealing a lack of tumor cell CD99 expression, and cytogenetics demonstrating normal chromosomal arrangement. Conversely, in our second case, a Ewing sarcoma/ PNET was diagnosed based on characteristic histology, robust tumor cell expression of CD99, and cytogenetic analysis revealing a chromosome 22q12 translocation.
The segregation of primary intraspinal PNETs into their respective subtypes has not been systematic throughout the literature. Of the 82 total cases in our review of the literature, only 16 (19.5%) included chromosome 22 rearrangement analysis while 37 (45.1%) reported on tumor cell expression of CD99 (Table 2) . Although it has been suggested that there are differences with regard to the clinical evolution and the optimal medical management of PNET subtypes, there is a paucity of data available in the literature to confirm that this is indeed the case. 48, 49, 75, 96 We therefore advocate that all spinal PNET specimens undergo standard subtyping analyses to facilitate advancements in our understanding of these tumors.
Management
From a clinical perspective, there are no standard protocols employed in the management of spinal PNETs. Instead, most treating physicians use empirical and often kitchen-sink type approaches. Furthermore, as the literature on these tumors consists mainly of case reports with short follow-up times, it is difficult to draw conclusions regarding the appropriateness of any single strategy. In general most centers employ surgical biopsy or resection, chemotherapy, and radiation therapy in their treatment protocols.
Surgery
The surgical treatment of spinal PNETs, as with most spinal tumors, is guided by the principles that one should: 1) decompress neural elements to prevent further neurological decline, 2) obtain an adequate tissue sample for pathological examination, and 3) resect as much tumor as can be safely removed. Exposure over the entire rostrocaudal extent of the tumor is generally necessary to accomplish these goals. While a standard laminectomy with preservation of the facet joints is usually performed in adults, laminoplasty may be considered in pediatric patients.
In our review of 82 reported cases, 81 underwent some form of open surgical procedure and 1 underwent stereotactic biopsy (Table 2 ). Of those cases from which the information could be extracted, GTR was achieved in 35% (20 of 57), STR was achieved in 51% (29 of 57), and biopsy only was achieved in 14% (8 of 57).
Adjuvant Therapy
Evidence of benefit from adjuvant therapy in treating spinal PNETs is anecdotal at best. Nevertheless, both radiation and chemotherapy are commonly used. The optimal radiation strategy, the necessity of full neural axis radiation in the setting of localized disease, and dosing are all controversial topics in the treatment of primary spinal PNETs. 94 In the cases we reviewed, 65 (83%) of 78 patients received radiation therapy (Table 2) . Total doses ranged from 30 Gy to 60 Gy. Some authors advocate for hyperfractionated radiotherapy, but there is currently no data to suggest any benefit to this strategy. 2 Much like the variety of radiation strategies employed, a multitude of chemotherapeutic agents have been advocated for use in patients with spinal PNETs ( Table 2 ). Regimens that combine high-dose chemotherapy and autologous stem cell rescue in addition to surgery and radiation have shown promising results in several reports.
75,96
Follow-Up and Prognosis
The prognosis in most cases of spinal PNETs appears to be poor with a median patient survival of 1 to 2 years. 48, 59 Approximately one-third of patients will exhibit cerebrospinal dissemination of their tumor. 39 Extraneural 
Conclusions
Primary spinal PNETs are devastating malignancies that appear to be more common than has previously been reported. The clinician should give consideration to the possibility of this diagnosis, especially in the setting of a young adult or child with an intraspinal mass. While there are no widely accepted standards for the management of spinal PNETs, we advocate complete resection when possible with the goals of neurological stabilization and obtaining sufficient tissue for accurate diagnosis. This should then be followed by an individualized combination of chemotherapy and/or radiation. As much remains to be learned about these tumors, especially regarding the prognostic implication of PNET subtyping, pathological samples should be analyzed for CD99 immunoreactivity and the (11;22) (q24;q12) translocation. Only by carefully delineating primary intraspinal PNET subtypes, as was completed in the 2 case illustrations we presented, will the clinical differences and optimal management strategies become apparent for these aggressive tumors. 
